Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2015; 50(11/12): 684-690
DOI: 10.1055/s-0041-105951
Fachwissen
Anästhesiologie & Intensivmedizin
© Georg Thieme Verlag Stuttgart · New York

Der Gerinnungsfaktor XIII – Pathophysiologie, Klinik und Therapie von Mangelzuständen

Coagulation factor XIII – Pathophysiology, clinic and therapy of factor XIII deficiency
Christian Friedrich Weber
1   Die Autoren haben zu gleichen Teilen zum Manuskript beigetragen und teilen sich die Erstautorenschaft.
,
Elisabeth Hannah Adam
1   Die Autoren haben zu gleichen Teilen zum Manuskript beigetragen und teilen sich die Erstautorenschaft.
,
Andreas Pape
,
Marina Jöst
,
Patrick Meybohm
,
Katja Schmitz
,
Kai Zacharowski
,
Martin Hermann
,
Dietmar Fries
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Transglutaminase Faktor XIII (FXIII) besitzt ein vielfältiges Wirkspektrum, das zentrale Funktionen in der sekundären Hämostase einschließt. Multifaktoriell bedingte FXIII-Mangelzustände können u. a.mit Aborten, Wundheilungsstörungen und lebensbedrohlichen Koagulopathien assoziiert sein. Die vorliegende Übersichtsarbeit beschreibt die physiologischen Funktionen von FXIII sowie Pathophysiologie, Diagnostik und Therapieoptionen von FXIII-Mangelzuständen.

Abstract

The complex activity of the transglutaminase factor XIII (FXIII) comprises central functions in secondary hemostasis. Congenital or acquired FXIII deficiencies may be associated with habitual abortions, impaired wound healing, coagulopathy and fatal hemorrhage. The present review describes physiological functions of FXIII, as well as pathophysiology, diagnostic and therapeutic options of FXIII deficiencies.

Kernaussagen

  • Faktor XIII (FXIII) nimmt als Transglutaminase eine Sonderstellung unter den Gerinnungsfaktoren ein.

  • FXIII besitzt geringe Substratspezifität. Sein Wirkspektrum schließt Funktionen bei der Hämostase, der Wundheilung, der Aufrechterhaltung einer Schwangerschaft und der Immunmodulation ein.

  • Kongenitale heterozygote Mangelzustände haben eine relativ hohe Prävalenz (ca. 1 : 1000) und sind klinisch häufig inapparent.

  • Sekundär erworbene Mangelzustände sind oft unspezifische Komorbidität internistischer Erkrankungen oder Folge von Blutverlust, Verbrauch und Dilution.

  • FXIII-Mangel kann mit Koagulopathie und lebensbedrohlichen Blutungen assoziiert sein.

  • Konventionelle Laborgerinnungsdiagnostik oder Point-of-Care-Verfahren wie die Thrombelastometrie erlauben keine Aussage über die FXIII-Aktivität.

  • Therapieoptionen bestehen in der Transfusion von Frischplasma bzw. der Applikation von pasteurisierten oder rekombinant hergestellten Faktorenkonzentraten.

Schlüsselwörter:

Faktor XIII - Gerinnung - Hämostase - Faktor-XIII-Defizit - Koagulopathie

Keywords:

factor XIII - coagulation - hemostasis - factor XIII deficiency - coagulopathy

Ergänzendes Material

 

  • Literatur

  • 1 Monroe DM, Hoffman M. What does it take to make the perfect clot?. ArteriosclerThrombVascBiol 2006; 26: 41-48
    PubMedGoogle Scholar
  • 2 Komaromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J ThrombHaemost 2011; 9: 9-20
    CrossrefPubMedGoogle Scholar
  • 3 Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J BiolChem 1973; 248: 1395-407
    PubMedGoogle Scholar
  • 4 Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33: 357-421
    CrossrefPubMedGoogle Scholar
  • 5 Schwartz ML, Pizzo SV, Hill RL, McKee PA. The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). J BiolChem 1971; 246: 5851-5854
    PubMedGoogle Scholar
  • 6 Katona E, Penzes K, Csapo A et al. Interaction of factor XIII subunits. Blood 2014; 123: 1757-1763
    CrossrefPubMedGoogle Scholar
  • 7 Mary A, Achyuthan KE, Greenberg CS. b-chains prevent the proteolytic inactivation of the a-chains of plasma factor XIII. BiochimBiophysActa 1988; 966: 328-335
    PubMedGoogle Scholar
  • 8 Souri M, Osaki T, Ichinose A. The non-catalytic B subunit of coagulation factor XIII accelerates fibrin cross-linking. J BiolChem 2015; 290: 12027-12039
    PubMedGoogle Scholar
  • 9 Muszbek L, Bereczky Z, Bagoly Z et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931-972
    CrossrefPubMedGoogle Scholar
  • 10 Dufner GS, Marbet GA. Factor XIII in man: a review. Hamostaseologie 2002; 22: 11-19
    PubMedGoogle Scholar
  • 11 Adany R. Intracellular factor XIII: cellular distribution of factor XIII subunit a in humans. SeminThrombHemost 1996; 22: 399-408
    PubMedGoogle Scholar
  • 12 Kradin RL, Lynch GW, Kurnick JT et al. Factor XIII A is synthesized and expressed on the surface of U937 cells and alveolar macrophages. Blood 1987; 69: 778-785
    PubMedGoogle Scholar
  • 13 Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94: 271-305
    CrossrefPubMedGoogle Scholar
  • 14 Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7: 229-242
    CrossrefPubMedGoogle Scholar
  • 15 Schroeder V, Kohler HP. New developments in the area of factor XIII. J ThrombHaemost 2013; 11: 234-244
    CrossrefPubMedGoogle Scholar
  • 16 Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. ThrombHaemost 2007; 97: 890-898
    PubMedGoogle Scholar
  • 17 Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. CurrOpinHematol 2007; 14: 236-241
    PubMedGoogle Scholar
  • 18 McKee PA, Mattock P, Hill RL. Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl AcadSci U S A 1970; 66: 738-744
    PubMedGoogle Scholar
  • 19 Sakata Y, Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-542
    CrossrefPubMedGoogle Scholar
  • 20 Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J BiolChem 1982; 257: 14767-14772
    PubMedGoogle Scholar
  • 21 Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 2011; 117: 6371-6374
    CrossrefPubMedGoogle Scholar
  • 22 Dirkmann D, Gorlinger K, Gisbertz C et al. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. AnesthAnalg 2012; 114: 1182-1188
    PubMedGoogle Scholar
  • 23 Shenkman B, Einav Y, Livnat T et al. In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. Blood Transfus 2014; 12: 78-84
    PubMedGoogle Scholar
  • 24 Noll T, Wozniak G. Factor XIII and endothelial barrier function. Hamostaseologie 2002; 22: 28-31
    PubMedGoogle Scholar
  • 25 Noll T, Wozniak G, McCarson K et al. Effect of factor XIII on endothelial barrier function. J Exp Med 1999; 189: 1373-1382
    CrossrefPubMedGoogle Scholar
  • 26 Naderi M, Dorgalaleh A, Alizadeh S et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100: 443-449
    CrossrefPubMedGoogle Scholar
  • 27 Hoetzenecker W, Guenova E, Mitev V et al. Treatment of pyoderma gangrenosum with topical factor XIII. Eur J Dermatol 2013; 23: 653-657
    PubMedGoogle Scholar
  • 28 Andersson C, Kvist PH, McElhinney K et al. Factor XIII transglutaminase supports the resolution of mucosal damage in experimental colitis. PLoS One 2015; 10
    PubMedGoogle Scholar
  • 29 Bregenzer N, Caesar I, Andus T et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group. Z Gastroenterol 1999; 37: 999-1004
    PubMedGoogle Scholar
  • 30 Floridon C, Nielsen O, Holund B et al. Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta 2000; 21: 754-762
    CrossrefPubMedGoogle Scholar
  • 31 Mello G, Parretti E, Gensini F et al. Maternal-fetal flow, negative events, and preeclampsia: role of ACE I/D polymorphism. Hypertension 2003; 41: 932-937
    CrossrefPubMedGoogle Scholar
  • 32 Koseki-Kuno S, Yamakawa M, Dickneite G, Ichinose A. Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood 2003; 102: 4410-4412
    CrossrefPubMedGoogle Scholar
  • 33 Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. ClinChem 2003; 49: 1081-1086
    PubMedGoogle Scholar
  • 34 Asahina T, Kobayashi T, Okada Y et al. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000; 21: 388-393
    CrossrefPubMedGoogle Scholar
  • 35 Boda Z, Pfliegler G, Muszbek L et al. Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A casereport. Haemostasis 1989; 19: 348-352
    PubMedGoogle Scholar
  • 36 Kobayashi T, Terao T, Kojima T et al. Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery. GynecolObstet Invest 1990; 29: 235-238
    PubMedGoogle Scholar
  • 37 Bremme KA. Haemostatic changes in pregnancy. Best Pract Res ClinHaematol 2003; 16: 153-168
    PubMedGoogle Scholar
  • 38 Karlsson O, Jeppsson A, Hellgren M. A longitudinal study of factor XIII activity, fibrinogen concentration, platelet count and clot strength during normal pregnancy. Thromb Res 2014; 134: 750-752
    CrossrefPubMedGoogle Scholar
  • 39 Sharief LT, Lawrie AS, Mackie IJ et al. Changes in factor XIII level during pregnancy. Haemophilia 2014; 20: 144-148
    CrossrefPubMedGoogle Scholar
  • 40 Wang Z, Wilhelmsson C, Hyrsl P et al. Pathogen entrapment by transglutaminase – a conserved early innate immune mechanism. PLoSPathog 2010; 6
    PubMedGoogle Scholar
  • 41 Loof TG, Morgelin M, Johansson L et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011; 118: 2589-2598
    CrossrefPubMedGoogle Scholar
  • 42 Biswas A, Ivaskevicius V, Seitz R et al. An update of the mutation profile of Factor 13 A and B genes. Blood Rev 2011; 25: 193-204
    CrossrefPubMedGoogle Scholar
  • 43 Kohler HP, Ariens RA, Whitaker P, Grant PJ. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. ThrombHaemost 1998; 80: 704-704
    PubMedGoogle Scholar
  • 44 Ariens RA, Philippou H, Nagaswami C et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995
    PubMedGoogle Scholar
  • 45 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J BiolChem 2000; 275: 20627-20631
    PubMedGoogle Scholar
  • 46 Antalfi B, Pongracz E, Csiki Z et al. Factor XIII-A subunit Val34Leu polymorphism in fatal hemorrhagic stroke. Int J Lab Hematol 2013; 35: 88-91
    CrossrefPubMedGoogle Scholar
  • 47 Voko Z, Bereczky Z, Katona E et al. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. ThrombHaemost 2007; 97: 458-463
    PubMedGoogle Scholar
  • 48 Kreutz RP, Bitar A, Owens J et al. Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. J Thromb Thrombolysis 2014; 38: 380-387
    CrossrefPubMedGoogle Scholar
  • 49 Kohler HP, Schroder V. Role of coagulation factor XIII in cardio- and cerebrovascular diseases. Hamostaseologie 2002; 22: 53-58
    PubMedGoogle Scholar
  • 50 Salazar-Sanchez L, Leon MP, Cartin M et al. The FXIIIVal34Leu, common and risk factors of venous thrombosis in early middle-age Costa Rican patients. Cell BiochemFunct 2007; 25: 739-745
    PubMedGoogle Scholar
  • 51 Endler G, Funk M, Haering D et al. Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?. Br J Haematol 2003; 120: 310-314
    CrossrefPubMedGoogle Scholar
  • 52 Shemirani AH, Antalfi B, Pongracz E et al. Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke. Blood Coagul Fibrinolysis 2014; 25: 364-368
    CrossrefPubMedGoogle Scholar
  • 53 Weber CF, Sanders JO, Friedrich K et al. Role of thrombelastometry for the monitoring of factor XIII. A prospective observational study in neurosurgical patients. Hamostaseologie 2011; 31: 111-117
    PubMedGoogle Scholar
  • 54 Katona E, Penzes K, Molnar E, Muszbek L. Measurement of factor XIII activity in plasma. ClinChem Lab Med 2012; 50: 1191-1202
    PubMedGoogle Scholar
  • 55 Oertel K, Hunfeld A, Specker E et al. A highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma. Anal Biochem 2007; 367: 152-158
    CrossrefPubMedGoogle Scholar
  • 56 Naderi M, Dorgalaleh A, Tabibian S et al. Current understanding in diagnosis and management of factor XIII deficiency. Iran J Ped HematolOncol 2013; 3: 164-172
    PubMedGoogle Scholar
  • 57 Fickenscher K, Aab A, Stuber W. A photometric assay for blood coagulation factor XIII. ThrombHaemost 1991; 65: 535-540
    PubMedGoogle Scholar
  • 58 Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897-905
    PubMedGoogle Scholar
  • 59 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. ThrombDiathHaemorrh 1960; 5: 179-186
    PubMedGoogle Scholar
  • 60 Odame JE, Chan AK, Wu JK, Breakey VR. Factor XIII deficiency management: a review of the literature. Blood Coagul Fibrinolysis 2014; 25: 199-205
    CrossrefPubMedGoogle Scholar
  • 61 Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-484
    CrossrefPubMedGoogle Scholar
  • 62 Ichinose A. Physiopathology and regulation of factor XIII. ThrombHaemost 2001; 86: 57-65
    PubMedGoogle Scholar
  • 63 Peyvandi F, Palla R, Menegatti M et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J ThrombHaemost 2012; 10: 615-621
    CrossrefPubMedGoogle Scholar
  • 64 Biswas A, Ivaskevicius V, Thomas A, Oldenburg J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 2014; 34: 160-166
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Nussbaum M, Morse BS. Plasma fibrin stabilizing factor activity in various diseases. Blood 1964; 23: 669-678
    PubMedGoogle Scholar
  • 66 Lorand L, Velasco PT, Murthy SN et al. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood 1999; 93: 909-917
    PubMedGoogle Scholar
  • 67 Lorand L, Velasco PT, Hill JM et al. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. ThrombHaemost 2002; 88: 919-923
    PubMedGoogle Scholar
  • 68 Souri M, Osaki T, Ichinose A. Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2 B2 assembly and steal FXIII-A from native FXIII-A2 B2. J ThrombHaemost 2015; 13: 802-814
    CrossrefPubMedGoogle Scholar
  • 69 Ichinose A, Osaki T, Souri M. Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies. Haemophilia 2015; 21: 653-658
    CrossrefPubMedGoogle Scholar
  • 70 Egbring R, Kroniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. SeminThrombHemost 1996; 22: 419-425
    PubMedGoogle Scholar
  • 71 Haas T, Korte W, Spielmann N et al. Perioperative course of FXIII in children undergoing major surgery. PaediatrAnaesth 2012; 22: 641-646
    PubMedGoogle Scholar
  • 72 Gerlach R, Tolle F, Raabe A et al. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33: 1618-1623
    CrossrefPubMedGoogle Scholar
  • 73 Bockeria LA, Samsonova NN, Yurlov IA et al. Dynamics of factor XIII levels after open heart surgery for congenital heart defects: do cyanotic and acyanotic patients differ?. PediatrCardiol 2014; 35: 1108-1115
    PubMedGoogle Scholar
  • 74 Kalbhenn J, Wittau N, Schmutz A et al. Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy. Perfusion 2015; 30: 675-682
    CrossrefPubMedGoogle Scholar
  • 75 Theusinger OM, Baulig W, Seifert B et al. Changes in coagulation in standard laboratory tests and ROTEM in trauma patients between on-scene and arrival in the emergency department. AnesthAnalg 2015; 120: 627-635
    PubMedGoogle Scholar
  • 76 Seitz R, Duckert F, Lopaciuk S et al. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. SeminThrombHemost 1996; 22: 415-418
    PubMedGoogle Scholar
  • 77 Ivaskevicius V, Biswas A, Bevans C et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010; 95: 956-962
    CrossrefPubMedGoogle Scholar
  • 78 Acharya SS, Coughlin A, Dimichele DM. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J ThrombHaemost 2004; 2: 248-256
    CrossrefPubMedGoogle Scholar
  • 79 Biswas A, Ivaskevicius V, Thomas A et al. Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function. Ann Hematol 2014; 93: 1665-1676
    CrossrefPubMedGoogle Scholar
  • 80 Wettstein P, Haeberli A, Stutz M et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. AnesthAnalg 2004; 99: 1564-1569
    PubMedGoogle Scholar
  • 81 Korte WC, Szadkowski C, Gahler A et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110: 239-245
    PubMedGoogle Scholar
  • 82 Godje O, Gallmeier U, Schelian M et al. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. ThoracCardiovascSurg 2006; 54: 26-33
    PubMedGoogle Scholar
  • 83 Fadoo Z, Merchant Q, Rehman KA. New developments in the management of congenital Factor XIII deficiency. J Blood Med 2013; 4: 65-73
    PubMedGoogle Scholar
  • 84 Kerlin B, Brand B, Inbal A et al. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. J ThrombHaemost 2014; 12: 2038-2043
    CrossrefPubMedGoogle Scholar
  • 85 Ashley C, Chang E, Davis J et al. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia 2015; 21: 102-108
    CrossrefPubMedGoogle Scholar
  • 86 Korte W. Fibrin monomer and factor XIII: a new concept for unexplained intraoperative coagulopathy. Hamostaseologie 2006; 26: 30-35
    PubMedGoogle Scholar
  • 87 Weber CF, Zacharowski K, Meybohm P et al. Hemotherapy algorithms for coagulopathic cardiac surgery patients. Clin Lab 2014; 60: 1059-1063
    PubMedGoogle Scholar
  • 88 Weber CF, Zacharowski K, Brun K et al. Basisalgorithmus für „Point-of-Care“ basierte Hämotherapie: Perioperative Versorgung koagulopathischer Patienten. Anaesthesist 2013; 62: 464-472
    CrossrefPubMedGoogle Scholar
  • 89 Kozek-Langenecker SA, Afshari A, Albaladejo P et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382
    CrossrefPubMedGoogle Scholar
  • 90 Scharrer I. Replacement therapy of coagulation factor preparations: antithrombin, FFP, PPSB, FXIII, rFVIIa. Hamostaseologie 2005; 25: 209-212
    PubMedGoogle Scholar